Platinum based chemotherapy for Ovarian Carcinoma

Background: The management of advanced epithelial ovarian cancer (EOC) has evolved to become a combination of initial cytoreductive surgery (CRS) followed by chemotherapy. Chemotherapy has been regarded as standard therapy for the majority of women with advanced EOC for several decades. A thorough understanding of drug resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. The aim of characterized by age of women, type, stage, grade and clinical staging of the tumor. Methods: Data from regimens containing platinum (cisplatin or carboplatin) used in treating ovarian carcinoma in Sarjito General Hospital were analyzed prospectively. Relative dose intensity was calculated as a fraction of the dosage of a drug in the standard regimen of cyclophosphamide, doxorubicin, and platinum. Results: The higher age of women will have lower response to chemotherapy. Women aged below 50 years old are much higher responsive to chemotherapy. Conclusion: Cisplatin based chemotherapy has a better response to ovarian carcinoma in earlier stage. In higher stage, it will give a complete removal of all macroscopic tumor tissue.